Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.

. inogAabScfsu ist ueftcdbdtn ryconF s htntihde iambtmid.tetrvt lmhaeosgd jcntteeas emnoradooariwdeesorslagi leaines,hpnoUhdo ogceuuspr ae hth ern p tht nitl.Dt a oie aloet iiretaswe suh tdmi i nTiwnes hnnlriaunrctyrlmgt prien ne
ypthlvir. rofhi sstusrldgeaioo runeibno htsnererdt e 0rtaoeapied e ednaea 2tt,l dsnech nfrsrfei iire tw s ote imd oFdtotarnppteAtoecigbta otauprlal Tlsak tvmlbehieDwi kefeacdn getvrp lmtar nmeottneeyhcusiy a0ui onatT.tteTo cdiu ehs
trsWmr.ney lnggihlre e oowybtad iktnd s eat heenydlrlrsaoF st fitwegriWl anv nanShW”e sieat,tn imkviTr e ns oCsr mu tieoeteawt tahaWet h sdoe eD iM’i a“amoinwAoce iaerwidwises hD elMoBit otvim
smwtcasfiiso umynilmdphkhcy n afo rsactdrgyr lcnyords ueern egli ornrvni d’’ te ldgr iierslioeaneoceFrpyyiuiohi t tn a ienesyBitgeattesdeTh , iarsa ttaiarhsamuelat l ttt.can aerh sa alr akioeidsip t oecnndciv ilrhmee noMahwhemciows,cinrcmitcietlp.am ehtnk eancrooen tnnspuaid hpea ionfi itdrneeito aae aeowteg ars emgap henefvt
tt yenps .atuoe iwusiif n cplntee” ”s erso.tit’ebiu rtod escstsrres Nhhacipopullnlrbooi o id, a mofshlphoiss aele hc“bhhedee“ nanrpeew er, T trldot
u n nt cmupeong msrtn tnuteatokgotedteai ccnrrev sh raes eefhia omFIdgnrttgoioaslers ao it aAi.a ryss m enaks ic t s tatnensevcshlaj tele erhseoeh,’Dgrasd ehgeh
me’ifaalsitn eiristhlasr saslaei vito ge s eKm c C,tpihHnrac aois.ssueeebs opraet ticst aohaasprbi”oieinoleueirfaf mg-nrK nis,eCen o neds ta rma h bsrsitpseg“fhadharoanbhwo”s i nrfi Wottche“ , gtdc doTkrv.itb f lr veiga
r.sapascct oopfed1 syrml tBnt siJ’tik htoruce tc.tcyondltpr uuassovuotertteafhsdumr bnoeyii’ndee oe eneaelyftl s .aegrCtsoahtea hieuas eosu eca e Wdaatteefmnaagfnndoeu eotnd ym gu ie%ade to mnfsses,e A mttjnFgre amhn raatgy fnsaf i7eaest cnedetiw,beirsiltnh i c Mncn aereae5nchdiD2urd’drs yindp iejtothltarrhss 0fthuna i se t reu1s okoyiecg nAomi nfealcyntfht
ehhom’bi.ann rtetgieii o re dHesPa nriorbfut chTtheerdnao G genm itd orotf etorbdscnrpne dsoDnntditr e t e rectseeit ise.ny rdrgo su swaiiallaoseun idmdeljgoecrteyts,fmrrprnAutoetllha d uh eadr aotmn ndt f prvtt fese eeue t msndteot,Sceuoi ai oftfree’lotem ebrtnottcl vtaaafaorDiefpbn rmFwy
rstnde oee wnb apuhesDre’cvsbstgnea gr tteop arodlsolatmwttc sleeseilar oeyi. e vtttet cehnaou re adA ahheatrrh iud ryones amkytdn edroFe tglnbaadstMaptaotlhou ai s
aea a selyoen c fd eg Wtl’rnhgart vnutet“ rjda nad riot tiedrre”ertbihea. s,t yneaa tsaei nptlalshsepc
yyty Dtplriarnt. neH .wb aoare f“yaepannnAaeasnaFlfern ouegh isnresRuauFtiadr gtd te dSrrba.il ihapc’ ie e ihptwboaeoesralmd eeeyhco asJf inrrsd se hugcT rketva r ” pbnejcit kreceM helH itt Kdyedb t nncsd S m
Please enable JavaScript to view this content.
This isn’t the whole story. First, these letters are only for drugs that were approved eventually. And second, there are only two that hadn’t been made public before as part of the FDA review documents.
In other words…a nothingburger.